Molecular Profiling of a Triple-negative Breast Cancer Cohort in India for EGFR and AR expression analyzed for patient outcomes showed a distinct subset of cellular co-expression

Pooja Vaid; Anirudha Puntambekar; Pranali Kanse; Shweta Kadu; Piyush Agrawal; Aditi Khatpe; Rituja Banale; Ruhi Reddy; Devaki A. Kelkar; Sridhar Hannenhalli; L S Shashidhara; Chaitanyanand Koppiker; Madhura Kulkarni

doi:10.1101/2024.10.25.24316141

Abstract

TNBC is the most aggressive breast cancer subtype, with a higher recurrence rate. TNBC proportion within breast cancer incidence in the Indian population is 22-30%. Despite the high incidence rate, the heterogeneity within TNBC subtype in Indian cohorts is not studied at scale.

Here, leveraging an Indian cohort of 93 TNBC patients, we evaluated the basal and LAR subtypes in terms of the expression of known markers such as EGFR and AR and further assessed the association of marker gene expression with patient outcome and treatment response.

In our cohort, 65% of the patients were EGFR-positive, 38% had positive AR expression, where both the subsets showed shorter disease-free survival outcomes. Additionally, 25% of the cohort showed AR and EGFR co-expression. Upon closer observation, using IHC and duplex staining, we noted that 15% of the tumors, in fact, had double-positive cancer cells, i.e., cellular co-expression of AR and EGFR. Patients with double-positive cells had poorer disease-free survival compared to the ones with the tissue-level co-expression of EGFR and AR but without cellular co-expression. The presence of EGFR+AR+ double-positive cells was further validated in publicly available single-cell data sets for TNBC patients from other ethnic backgrounds, albeit to a lesser extent than what was observed in our Indian cohort. Overall, our results highlight the heterogeneous nature of Indian TNBC tumors and provide further insight into ethnic variation in TNBC presentation that can be further exploited for precision and personalized targeted therapy.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

MK would like to acknowledge the DBT- Ramalingaswami re-entry fellowship and DBT-Basic Research in Biology awarded by DBT-India. LSS would like to acknowledge the DST-JC Bose Research Fellowship, a Mphasis grant to TSB at Ashoka University. The research grant to CTCR is supported by Bajaj Auto Ltd. PV would like to acknowledge Ashoka University for PhD fellowship.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics committee/IRB of Prashanti Cancer Care Mission, Pune gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes